Figure 2.
Figure 2. In vivo function of TCR-modified T cells in a self-tolerant setting. (A) Analysis of blood cells and blood-glucose levels of RIP-OVAhi mice that received 1 × 105 F5 (□) or OT-I (•) transduced T cells followed by inflova infection. (B) Analysis of blood cells and blood-glucose levels of RIP-OVAhi mice that received 1 × 106 F5 (□) or OT-I (•) transduced T cells followed by rVV-OVA infection; blood was sampled 3 to 15 days after infection. (Left and middle) Closed circles and open squares represent TCR-transduced T-cell responses in individual mice; bars, averages. (Right) Blood-glucose levels were measured to monitor development of type I diabetes. RIP-OVAhi mice that were infected with inflova were killed upon development of diabetes; RIP-OVAhi mice that were infected with rVV-OVA were treated with insulin implants upon development of diabetes.

In vivo function of TCR-modified T cells in a self-tolerant setting. (A) Analysis of blood cells and blood-glucose levels of RIP-OVAhi mice that received 1 × 105 F5 (□) or OT-I (•) transduced T cells followed by inflova infection. (B) Analysis of blood cells and blood-glucose levels of RIP-OVAhi mice that received 1 × 106 F5 (□) or OT-I (•) transduced T cells followed by rVV-OVA infection; blood was sampled 3 to 15 days after infection. (Left and middle) Closed circles and open squares represent TCR-transduced T-cell responses in individual mice; bars, averages. (Right) Blood-glucose levels were measured to monitor development of type I diabetes. RIP-OVAhi mice that were infected with inflova were killed upon development of diabetes; RIP-OVAhi mice that were infected with rVV-OVA were treated with insulin implants upon development of diabetes.

Close Modal

or Create an Account

Close Modal
Close Modal